Nonhuman primates (NHPs) serve a crucial role in translational research as animal models for exploring the pathogenesis of infectious and noninfectious diseases, and for testing of biologic therapies and vaccines. While many human diagnostic immunologic reagents cross react with the primate species commonly employed in translational research, gaps exist for a substantial number of reagent targets. Furthermore, antibodies that target specific immune functions or deplete specific lymphocyte subpopulations in vivo have proven valuable in defining disease mechanisms or can be used as proof-of-concept for new therapies. For the past 15 years, the NIH Nonhuman Primate Reagent Resource has responded to needs of the scientific community by developing, manufacturing and distributing NHP- specific reagents for in vitro diagnostics and for in vivo use. Utilization of this resource has grown dramatically since this program's inception. During the last budget year, we fulfilled 500 reagent requests from 126 investigators and distributed over 300 grams of recombinant antibody for administration to NHPs. Taking advantage of scientific advances and technological improvements in antibody development, engineering, expression and vectoring, we will continue to support the scientific community utilizing NHP models across all scientific disciplines.
The Nonhuman Primate Reagent Resource develops, manufactures and distributes antibody research reagents for use as tools in nonhuman primate models of disease. These antibody tools help investigators to develop treatments and vaccines for many different infectious diseases. Some antibodies are also being evaluated as therapeutics for autoimmune diseases and in organ transplantation.
|Santangelo, P J; Cicala, C; Byrareddy, S N et al. (2018) Early treatment of SIV+ macaques with an ?4?7 mAb alters virus distribution and preserves CD4+ T cells in later stages of infection. Mucosal Immunol 11:932-946|
|Calenda, Giulia; Keawvichit, Rassamon; Arrode-Brusés, Géraldine et al. (2018) Integrin ?4?7 Blockade Preferentially Impacts CCR6+ Lymphocyte Subsets in Blood and Mucosal Tissues of Naive Rhesus Macaques. J Immunol 200:810-820|
|Zhang, Tianshu; Azimzadeh, Agnes M; Sun, Wenji et al. (2018) Selective CD28 Inhibition Modulates Alloimmunity and Cardiac Allograft Vasculopathy in Anti-CD154-Treated Monkeys. Transplantation 102:e90-e100|
|Min, Byoung-Hoon; Shin, Jun-Seop; Kim, Jong-Min et al. (2018) Delayed revascularization of islets after transplantation by IL-6 blockade in pig to non-human primate islet xenotransplantation model. Xenotransplantation 25:|
|Hotta, Kiyohiko; Oura, Tetsu; Dehnadi, Abbas et al. (2018) Long-term Nonhuman Primate Renal Allograft Survival Without Ongoing Immunosuppression in Recipients of Delayed Donor Bone Marrow Transplantation. Transplantation 102:e128-e136|
|Nawaz, Fatima; Goes, Livia R; Ray, Jocelyn C et al. (2018) MAdCAM costimulation through Integrin-?4?7 promotes HIV replication. Mucosal Immunol 11:1342-1351|
|O'Neill, Natalie A; Zhang, Tianshu; Braileanu, Gheorghe et al. (2018) Pilot Study of Delayed ICOS/ICOS-L Blockade With ?CD40 to Modulate Pathogenic Alloimmunity in a Primate Cardiac Allograft Model. Transplant Direct 4:e344|
|Choi, Se Hyun; Yoon, Chang Ho; Lee, Hyun Ju et al. (2018) Long-term safety outcome of systemic immunosuppression in pig-to-nonhuman primate corneal xenotransplantation. Xenotransplantation 25:e12442|
|Lee, Jae-Il; Kim, Jiyeon; Choi, Yun-Jung et al. (2018) The effect of epitope-based ligation of ICAM-1 on survival and retransplantation of pig islets in nonhuman primates. Xenotransplantation 25:|
|Shin, Jun-Seop; Kim, Jong-Min; Min, Byoung-Hoon et al. (2018) Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression. Xenotransplantation 25:|
Showing the most recent 10 out of 74 publications